Inflammatory Myositis Market: Accelerating Growth and Pipeline Impact by 2034 - DelveInsight

DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Inflammatory Myositis landscape.
DelveInsight's report, "Inflammatory Myositis Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Inflammatory Myositis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.
Additionally, it examines Inflammatory Myositis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Inflammatory Myositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Myositis Market Forecast
https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Inflammatory Myositis Market Report:
• The Inflammatory Myositis market size was valued approximately USD 589 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• The market size across the 7MM is expected to grow at a CAGR of approximately 11.7%, driven by heightened disease awareness and the introduction of emerging therapies.
• In 2023, Germany and Italy held the largest market sizes among EU countries, with USD 69 million and USD 47 million, respectively, while Spain had the smallest market size at USD 21 million.
• Japan had a market size of USD 72 million in 2023, but this is expected to shift in the coming forecast period.
• In 2023, there were approximately 188 thousand diagnosed cases of inflammatory myositis across the 7MM, with 92 thousand cases estimated to be from the US. These numbers are expected to rise over the forecast period.
• The diagnosed prevalent cases of inflammatory myositis were classified into specific types: PM, DM, and IBM, with 76 thousand, 84 thousand, and 27 thousand cases respectively across the 7MM in 2023. These numbers are expected to rise by 2034.
• In 2023, the age-specific cases of inflammatory myositis in the EU4 and the UK were categorized as follows: 3 thousand cases in individuals aged 0-17 years, 12 thousand in those aged 18-44 years, 25 thousand in the 45-64 age group, and 29 thousand cases in individuals aged 65 years and older.
• In 2023, the diagnosed prevalent cases of inflammatory myositis in Japan were further categorized by gender, with 10 thousand cases in males and 15 thousand cases in females.
• Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others
• Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others
• The Inflammatory Myositis epidemiology based on gender analyzed that females are more susceptible to suffer from Inflammatory myositis when compared to the male population, in the 7MM
• The Inflammatory Myositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Myositis pipeline products will significantly revolutionize the Inflammatory Myositis market dynamics.

Inflammatory Myositis Overview
Inflammatory myositis is a group of rare autoimmune disorders characterized by inflammation and weakness of the muscles. These conditions involve inflammation of the muscles (myositis), leading to muscle weakness, pain, and fatigue. There are several types of inflammatory myositis, including polymyositis, dermatomyositis, and inclusion body myositis, each with its own specific features and patterns of muscle involvement.

Get a Free sample for the Inflammatory Myositis Market Report:
https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key Trends in Inflammatory Myositis Therapeutics Market:
• Shift toward targeted and biologic therapies: Development is moving beyond broad immunosuppressants to targeted agents such as JAK inhibitors, monoclonal antibodies, and complement inhibitors addressing specific immune pathways.
• Rising focus on rare myositis subtypes: Increased research in dermatomyositis, polymyositis, immune-mediated necrotizing myopathy (IMNM), and antisynthetase syndrome is expanding indication-specific treatment strategies.
• Growing clinical trial activity and pipeline diversification: Pharmaceutical and biotech companies are advancing novel mechanisms, including interferon pathway inhibitors and B-cell-directed therapies, strengthening the late-stage pipeline.
• Improved diagnostics and biomarker-driven treatment: Advances in autoantibody testing and imaging are enabling earlier diagnosis, better patient stratification, and more personalized therapeutic approaches.
• Increasing regulatory incentives for rare diseases: Orphan drug designations, accelerated approvals, and supportive reimbursement policies are encouraging innovation and market entry in inflammatory myositis therapeutics.

Inflammatory Myositis Epidemiology
The Inflammatory Myositis epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Inflammatory Myositis Epidemiology Segmentation:
The Inflammatory Myositis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Inflammatory Myositis
• Prevalent Cases of Inflammatory Myositis by severity
• Gender-specific Prevalence of Inflammatory Myositis
• Diagnosed Cases of Episodic and Chronic Inflammatory Myositis

Download the report to understand which factors are driving Inflammatory Myositis epidemiology trends @ Inflammatory Myositis Epidemiology Forecast
https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Development In The Inflammatory Myositis Treatment Landscape:
• In December 2024, argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the lives of individuals with severe autoimmune diseases, has announced its decision to advance the development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study for adults with idiopathic inflammatory myopathies (IIM or myositis). This decision follows an analysis of topline data from the Phase 2 portion of the trial. The ALKIVIA study will continue enrolling patients across three myositis subtypes: immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).

Inflammatory Myositis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Myositis market or expected to get launched during the study period. The analysis covers Inflammatory Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Inflammatory Myositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Inflammatory Myositis Therapies and Key Companies
• Dazukibart (PF-06823859): Pfizer
• Hizentra: CSL Behring
• Efgartigimod: Argenx
• Brepocitinib: Priovant Therapeutics/Roivant
• Ultomiris: Alexion Pharmaceuticals
• PF-06823859: Pfizer
• Daxdilimab: Horizon Therapeutics
• Baricitinib: Eli Lilly and Company
• Nipocalimab: Janssen Research & Development
• PF-06823859: Pfizer
• Froniglutide: Immunoforge Co. Ltd.
• Infliximab: Schering-Plough
• Lovaza: GlaxoSmithKline
• Rituximab: Roche Pharma AG

Discover more about therapies set to grab major Inflammatory Myositis market share @ Inflammatory Myositis Treatment Market
https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Inflammatory Myositis Market Drivers
• High unmet need and limited approved therapies: Many patients rely on corticosteroids and immunosuppressants, driving demand for safer, disease-modifying treatments.
• Advances in immunology and precision medicine: Improved understanding of immune pathways and autoantibody profiles is enabling development of targeted biologics and novel mechanisms.
• Rising disease awareness and improved diagnosis: Better recognition of subtypes such as dermatomyositis and polymyositis, along with advanced diagnostic tools, is expanding the treated population.
• Growing clinical trial activity and orphan drug incentives: Regulatory support for rare diseases is encouraging biopharma investment and pipeline growth.
• Increasing focus on steroid-sparing therapies: The need to reduce long-term corticosteroid toxicity is accelerating adoption of targeted and combination approaches.

Inflammatory Myositis Market Barriers
• Rarity and heterogeneity of the disease: Small, diverse patient populations complicate clinical trial design and slow regulatory approval.
• Limited clinical endpoints and biomarkers: Lack of standardized, sensitive outcome measures makes efficacy assessment challenging.
• Safety concerns with immunosuppressive therapies: Risk of infections and long-term adverse effects may limit broader use.
• High development and treatment costs: Rare-disease drug development leads to premium pricing and potential reimbursement constraints.
• Slow patient recruitment and long trial timelines: Difficulty in enrolling appropriate patients can delay clinical development and market entry.

Scope of the Inflammatory Myositis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Inflammatory Myositis Companies: CSL Behring, Argenx, Priovant Therapeutics/Roivant, Alexion Pharmaceuticals, Pfizer, Horizon Therapeutics, Eli Lilly and Company, Janssen Research & Development, Pfizer, Immunoforge Co. Ltd., Schering-Plough, GlaxoSmithKline, Roche Pharma AG, and others
• Key Inflammatory Myositis Therapies: Dazukibart (PF-06823859), Hizentra, Efgartigimod, Brepocitinib, Ultomiris, PF-06823859, Daxdilimab, Baricitinib, Nipocalimab, PF-06823859, Froniglutide, Infliximab, Lovaza, Rituximab, and others
• Inflammatory Myositis Therapeutic Assessment: Inflammatory Myositis current marketed and Inflammatory Myositis emerging therapies
• Inflammatory Myositis Market Dynamics: Inflammatory Myositis market drivers and Inflammatory Myositis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Inflammatory Myositis Unmet Needs, KOL's views, Analyst's views, Inflammatory Myositis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.